San Francisco startup Framework Therapeutics is also engaged on an oral, when-day-to-day GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s anticipations in June any time a mid-stage study confirmed regular weight loss of all over 6% and it ideas to get started on A further mid-stage demo to the top of the year—that founder and CEO R… Read More